Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Сердечно-сосудистый континуум: возможности b-адреноблокаторов
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Полный текст
Список литературы
1. Карпов Ю.А., Шубина А.Т. b-Блокаторы сегодня: на передовых рубежах в борьбе с сердечно-сосудистыми заболеваниями. Рус. мед. журн. 2004; 12 (15): 901–4.
2. Reiter MJ. Cardiovascular drug class specificity: b-blockers. Progress in Cardiovasс Dis 2004; 47 (1): 11–33.
3. АСС/АНА 2002 Guidelines Update for the management of patients with chronic stable angina – summary article. A Report of the ACC/AHA Task Force on Practice Guidelines [Committee on management of patients with chronic stable angina]. Circulation 2003; 107: 149–58.
4. Диагностика и лечение стабильной стенокардии. Рекомендации ВНОК (2-й пересмотр), 2008.
5. Документ о соглашении экспертов по блокаторам b-адренергических рецепторов. Рабочая группа Европейского общества кардиологов по бета-блокаторам. Кардиоваск. тер. и проф. 2005; 1: 99–124.
6. Лупанов В.П. Лечение больных ишемической болезнью сердца после коронарного шунтирования и чрескожных коронарных вмешательств. Атмосфера. Кардиология. 2007; 3: 18–24.
7. Рекомендации РМОАГ, ВНОК по АГ.
8. Bangalore S, Wild D, Parkar S et al. Beta-blockers for primary prevention of heart failure in patients with hypertension: insights from a meta-analysis. JACC 2008; 52: 1062–72.
9. Nuttall SL, Routledge HC, Kendall MJ. A comparison of the beta1-selectivity of three beta-blockers. J Clin Pharmacol 2003; 28 (3): 179–86.
10. Warrington SJ, Johnston A, Lewis Y et al. Bisoprolol: studies of potential interactions with theophylline and warfarin in healthy volunteers. J Cardiovasc Pharmacol 1990; 16 (Suppl 5): 164–8.
11. Lithell HL. Effect of antihypertensive drugs on insulin, glucose and lipid metabolism. Diabetes Care 1991; 14: 203–9.
12. Кукес В.Г., Остроумова О.Д., Батурина А.М., Зыкова А.А.
b-Блокаторы в лечении артериальной гипертонии у больных с сахарным диабетом: противопоказание или препараты выбора? Рус. мед. журн. 2002; 10: 446–9.
13. Linen P Biochemical mechanisms involved in the beta-blocker induced changes in serum lipoproteins. Am Heart J 1992; 124: 549–56.
14. Chatterjee SS. J Cardiovasc Pharmacol 1986; 8 (Suppl. 11): 74–7.
15. Dorow P, Bethge H, Tonnesmann U. Effects of single oral doses of bisoprolol and atenolol on airway function in nonasthmatic chronic obstructive lung disease and angina pectoris. Eur J Clin Pharmacol 1986; 31: 143–7.
16. Остроумова О.Д., Батутина А.М. Выбор безопасного
b-блокатора у больных с сопутствующими хроническими обструктивными заболеваниями легких: преимущества бисопролола. Рус. мед. журн. 2003; 11 (9): 548–51.
17. Gosse P, Roudaut R, Herrero G et al. Beta-blockers vs angiotensin-converting enzyme inhibitors in hypertension: effects on left ventricular hypertrophy. J Cardiovasc Pharmacol 1990; 16 (Suppl. S): S145–50.
18. Frishman W, Bryzinski B, Coulson L et al. A multifactorial trial design to assess combination therapy in hypertension. Arch Inter Med 1994; 154: 1461–8.
19. Katritsis DG, Panagiotakos DB, Karvouni E et al. Comparison of effectiveness of carvedilol versus bisoprolol for maintenance of sinus rhythm after cardioversion of persistent atrial fibrillation. Am J Cardiol 2003; 92 (9): 1116–9.
20. Ishiguro H, Ikeda T, Abe A et al. Antiarrhythmic effect of bisoprolol, a highly selective beta1-blocker, in patients with paroxysmal atrial fibrillation. Int Heart J 2008; 49 (3): 281–93.
21. Plewan A, Lehmann G, Ndrepepa G et al. Maintenance of sinus rhythm after electrical cardioversion of persistent atrial fibrillation; sotalol vs bisoprolol. Eur Heart J 2001; 22 (16): 1504–10.
22. Steilaty G, Madi-Jebara S, Yazigi A et al. Postoperative oral amiodarone versus oral bisoprolol as prophylaxis against atrial fibrillation after coronary bypass graft surgery: a prospective randomized trial. Int J Cardiol 2009; 117 (2): 116–22.
23. Singh BN. CIBIS, MERIT-HF, and COPERNICUS trial outcomes: do they complete the chapter on beta-adrenergic blockers as antiarrhytmic and antifibrillatory drugs? J Cardiovasc Pharmacol Ther 2001; 6 (2): 107–10.
24. Арутюнов Г.П. Бета-блокаторы и сердечная недостаточность. Сердечная недостаточность. 2002; 1: 27–8.
25. CIBIS Investigators and Committees. A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study. Circulation 1994; 90 (4): 1765–73.
26. CIBIS-II Study Group. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II); a randomised trial. Lancet 1999; 353: 9–13.
27. Simon T, Mary-Krause M, Funck-Brentano C et al. Bisoprolol dose-response relationship in patients with congestive heart failure: a subgroup analysis in the cardiac insufficiency bisoprolol study (CIBIS II). Eur Heart J 2003; 24 (6): 552–9.
28. Willenheimer R, van Veldhuisen DJ, Silke B et al. CIBIS III Investigators Effect on survival and hospitalization of initiating treatment for chronic heart failure with bisoprolol followed by enalapril, as compared with the opposite sequence: results of the randomized Cardiac Insufficiency Bisoprolol Study (CIBIS III). Circulation 2005; 112 (16): 2426–35.
29. CIBIS Investigators and Committees. A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study. Circulation 1994; 90 (4): 1765–73.
30. Prager G, Wagner G. Effect of bisoprolol in coronary heart disease. Effect on cardiovascular parameters and ischemic ST depression: studies on the duration of the effect. Dtsch Med Wochenschr 1984; 109 (50): 1914–7.
31. Von Armin. Prognostic significance of transient ischemic episodes: response to treatment shows improved prognosis. Results of the Total Ischemic Burden Bisoprolol Study (TIBBS) follow-up. J Am Coll Cardiol 1996; 28: 20–4.
32. Poldermans D, Boersma E, Bax J et al. The effect of bisoprolol on perioperative mortality and myocardial infarction in high-risk patients undergoing vascular surgery. N Engl J Med 1999; 341: 1789–94.
33. Yusuf S, Peto R, Lewis J et al. Beta-blocade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 1985; 27 (5): 335–71.
34. Kjeksus JK, Gilpin E, Cali G et al. Diabetic patients and beta-blockers after acute myocardial infarction. Eur Heart J 1990: 11: 43–50.
35. Chen J, Marciniac TA, Radford MJ et al. Beta-blocker therapy for secondary prevention of myocardial infarction in elderly diabetic patients. JACC 1999; 34: 1388–94.
2. Reiter MJ. Cardiovascular drug class specificity: b-blockers. Progress in Cardiovasс Dis 2004; 47 (1): 11–33.
3. АСС/АНА 2002 Guidelines Update for the management of patients with chronic stable angina – summary article. A Report of the ACC/AHA Task Force on Practice Guidelines [Committee on management of patients with chronic stable angina]. Circulation 2003; 107: 149–58.
4. Диагностика и лечение стабильной стенокардии. Рекомендации ВНОК (2-й пересмотр), 2008.
5. Документ о соглашении экспертов по блокаторам b-адренергических рецепторов. Рабочая группа Европейского общества кардиологов по бета-блокаторам. Кардиоваск. тер. и проф. 2005; 1: 99–124.
6. Лупанов В.П. Лечение больных ишемической болезнью сердца после коронарного шунтирования и чрескожных коронарных вмешательств. Атмосфера. Кардиология. 2007; 3: 18–24.
7. Рекомендации РМОАГ, ВНОК по АГ.
8. Bangalore S, Wild D, Parkar S et al. Beta-blockers for primary prevention of heart failure in patients with hypertension: insights from a meta-analysis. JACC 2008; 52: 1062–72.
9. Nuttall SL, Routledge HC, Kendall MJ. A comparison of the beta1-selectivity of three beta-blockers. J Clin Pharmacol 2003; 28 (3): 179–86.
10. Warrington SJ, Johnston A, Lewis Y et al. Bisoprolol: studies of potential interactions with theophylline and warfarin in healthy volunteers. J Cardiovasc Pharmacol 1990; 16 (Suppl 5): 164–8.
11. Lithell HL. Effect of antihypertensive drugs on insulin, glucose and lipid metabolism. Diabetes Care 1991; 14: 203–9.
12. Кукес В.Г., Остроумова О.Д., Батурина А.М., Зыкова А.А.
b-Блокаторы в лечении артериальной гипертонии у больных с сахарным диабетом: противопоказание или препараты выбора? Рус. мед. журн. 2002; 10: 446–9.
13. Linen P Biochemical mechanisms involved in the beta-blocker induced changes in serum lipoproteins. Am Heart J 1992; 124: 549–56.
14. Chatterjee SS. J Cardiovasc Pharmacol 1986; 8 (Suppl. 11): 74–7.
15. Dorow P, Bethge H, Tonnesmann U. Effects of single oral doses of bisoprolol and atenolol on airway function in nonasthmatic chronic obstructive lung disease and angina pectoris. Eur J Clin Pharmacol 1986; 31: 143–7.
16. Остроумова О.Д., Батутина А.М. Выбор безопасного
b-блокатора у больных с сопутствующими хроническими обструктивными заболеваниями легких: преимущества бисопролола. Рус. мед. журн. 2003; 11 (9): 548–51.
17. Gosse P, Roudaut R, Herrero G et al. Beta-blockers vs angiotensin-converting enzyme inhibitors in hypertension: effects on left ventricular hypertrophy. J Cardiovasc Pharmacol 1990; 16 (Suppl. S): S145–50.
18. Frishman W, Bryzinski B, Coulson L et al. A multifactorial trial design to assess combination therapy in hypertension. Arch Inter Med 1994; 154: 1461–8.
19. Katritsis DG, Panagiotakos DB, Karvouni E et al. Comparison of effectiveness of carvedilol versus bisoprolol for maintenance of sinus rhythm after cardioversion of persistent atrial fibrillation. Am J Cardiol 2003; 92 (9): 1116–9.
20. Ishiguro H, Ikeda T, Abe A et al. Antiarrhythmic effect of bisoprolol, a highly selective beta1-blocker, in patients with paroxysmal atrial fibrillation. Int Heart J 2008; 49 (3): 281–93.
21. Plewan A, Lehmann G, Ndrepepa G et al. Maintenance of sinus rhythm after electrical cardioversion of persistent atrial fibrillation; sotalol vs bisoprolol. Eur Heart J 2001; 22 (16): 1504–10.
22. Steilaty G, Madi-Jebara S, Yazigi A et al. Postoperative oral amiodarone versus oral bisoprolol as prophylaxis against atrial fibrillation after coronary bypass graft surgery: a prospective randomized trial. Int J Cardiol 2009; 117 (2): 116–22.
23. Singh BN. CIBIS, MERIT-HF, and COPERNICUS trial outcomes: do they complete the chapter on beta-adrenergic blockers as antiarrhytmic and antifibrillatory drugs? J Cardiovasc Pharmacol Ther 2001; 6 (2): 107–10.
24. Арутюнов Г.П. Бета-блокаторы и сердечная недостаточность. Сердечная недостаточность. 2002; 1: 27–8.
25. CIBIS Investigators and Committees. A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study. Circulation 1994; 90 (4): 1765–73.
26. CIBIS-II Study Group. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II); a randomised trial. Lancet 1999; 353: 9–13.
27. Simon T, Mary-Krause M, Funck-Brentano C et al. Bisoprolol dose-response relationship in patients with congestive heart failure: a subgroup analysis in the cardiac insufficiency bisoprolol study (CIBIS II). Eur Heart J 2003; 24 (6): 552–9.
28. Willenheimer R, van Veldhuisen DJ, Silke B et al. CIBIS III Investigators Effect on survival and hospitalization of initiating treatment for chronic heart failure with bisoprolol followed by enalapril, as compared with the opposite sequence: results of the randomized Cardiac Insufficiency Bisoprolol Study (CIBIS III). Circulation 2005; 112 (16): 2426–35.
29. CIBIS Investigators and Committees. A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study. Circulation 1994; 90 (4): 1765–73.
30. Prager G, Wagner G. Effect of bisoprolol in coronary heart disease. Effect on cardiovascular parameters and ischemic ST depression: studies on the duration of the effect. Dtsch Med Wochenschr 1984; 109 (50): 1914–7.
31. Von Armin. Prognostic significance of transient ischemic episodes: response to treatment shows improved prognosis. Results of the Total Ischemic Burden Bisoprolol Study (TIBBS) follow-up. J Am Coll Cardiol 1996; 28: 20–4.
32. Poldermans D, Boersma E, Bax J et al. The effect of bisoprolol on perioperative mortality and myocardial infarction in high-risk patients undergoing vascular surgery. N Engl J Med 1999; 341: 1789–94.
33. Yusuf S, Peto R, Lewis J et al. Beta-blocade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 1985; 27 (5): 335–71.
34. Kjeksus JK, Gilpin E, Cali G et al. Diabetic patients and beta-blockers after acute myocardial infarction. Eur Heart J 1990: 11: 43–50.
35. Chen J, Marciniac TA, Radford MJ et al. Beta-blocker therapy for secondary prevention of myocardial infarction in elderly diabetic patients. JACC 1999; 34: 1388–94.
Авторы
Г.А.Барышникова, С.А.Чорбинская, И.И.Степанова, Н.В.Чупрова
Кафедра семейной медицины ФГБУ Учебно-научный медицинский центр Управления делами Президента РФ, Москва
Кафедра семейной медицины ФГБУ Учебно-научный медицинский центр Управления делами Президента РФ, Москва
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.